CEFOTAXIME SODIUM (sef-oh-taks'eem) Claforan Classifications: antiinfective; beta-lactam antibiotic; third-generation cephalosporin Pregnancy Category: B |
500 mg, 1 g, 2 g injection
Broad-spectrum semi-synthetic third-generation cephalosporin antibiotic. Preferentially binds to one or more of the penicillin-binding proteins (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis, thus killing the bacteria.
Generally active against a wide variety of gram-negative bacteria including most of the Enterobacteriaceae. Also active against some organisms resistant to first and second generation cephalosporins and currently available aminoglycoside antibiotics and penicillins. Used in the treatment of gram-negative adult bacillary meningitis, neonatal and childhood meningitis, and Enterobacteriaceae. Effectively treats bone and joint infections, CNS infections, gynecologic infections and gonorrhea, lower respiratory tract infections, intra-abdominal infections, skin and urinary tract infections, and is used for surgical prophylaxis to reduce or eliminate infection.
Serious infections of lower respiratory tract, skin and skin structures, bones and joints, CNS (including meningitis and ventriculitis), gynecologic and GU tract infections, including uncomplicated gonococcal infections caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). Also used to treat bacteremia or septicemia, intra-abdominal infections, and for perioperative prophylaxis.
Currently recommended by CDC for treatment of disseminated gonococcal infections (gonococcal arthritis-dermatitis syndrome) and as drug of choice for gonococcal ophthalmia caused by PPNG in adults, children, and neonates.
Hypersensitivity to cephalosporins and other beta-lactam antibiotics; pregnancy (category B).
History of type I hypersensitivity reactions to penicillin; history of allergy to other beta-lactam; antibiotics; renal impairment; history of colitis or other GI disease; lactation.
Moderate to Severe Infections Adult: IV/IM 12 g q812h, up to 2 g q4h (max: 12 g/d) Child: IV/IM 1wk: 50 mg/kg q12h; 14 wk: 100200 mg/kg/24h divided q612h; 1 mo12 y: 100200 mg/kg/d divided q48h (max: 12 g/24h) Surgical Prophylaxis Adult: IV/IM 1 g 3090 min before surgery |
Intravenous
PREPARE: Direct: Add 10 mL diluent to vial with 1 or 2 g drug providing a solution containing 95 or 180 mg/mL, respectively. Intermittent: To 1 or 2 g drug add 50 or 100 mL D5W, NS, D5/NS, D5/.45% NaCl, RL, or other compatible diluent. Continuous: Dilute in 5001000 mL compatible IV solution. ADMINISTER: Direct: Give over 35 min. Intermittent: Give over 2030 min, preferably via butterfly or scalp vein-type needles. Continuous: Infuse over 624 h. INCOMPATIBILITIES Solution/additive: aminoglycosides, aminophylline, doxapram, sodium bicarbonate, vancomycin. Y-site: Allopurinol, aminoglycosides, aminophylline, azithromycin, doxapram, filgrastim, fluconazole, gemcitabine, hetastarch, sodium bicarbonate; pentamidine, vancomycin. |
May cause falsely elevated serum or urine creatinine values (Jaffe reaction). False-positive reactions for urine glucose have not been reported using copper sulfate reduction methods, e.g., Benedict's, Clinitest: however, since it has occurred with other cephalosporins, it may be advisable to use glucose oxidase tests (Clinistix, TesTape, Diastix). Positive direct antiglobulin (Coombs') test results may interfere with hematologic studies and cross-matching procedures.
Assessment & Drug Effects
Patient & Family Education